MUSC Psychiatry Chair Update
January 26, 2017

Thomas W. Uhde, MD
Department of Psychiatry and Behavioral Sciences & Institute of Psychiatry
For anyone who is requesting promotion or tenure effective January 1, 2018, all promotion and tenure requests must be received in the Chairman’s office no later than February 9, 2017, in the form of complete packets accompanied by a letter of recommendation from your Division Director. Packets with checklists, requests for materials, and forms specific for regular and modified faculty have been developed to make the submission process more straightforward. Packets are available on the College of Medicine’s website. Follow this link: http://academicdepartments.musc.edu/com/faculty/apt/musc/index.html.

Promotion to Associate Professor or Professor requires a minimum of four letters of recommendation, addressed to the Departmental Chair. Individuals selected to write the minimum four letters should be non-MUSC faculty in the candidate’s field at the academic rank of professor or its equivalent stature. At least two of these individuals should not be associated with the candidate by having been past mentors/teachers/students/trainees. We ask that you provide 4-6 names of individuals that we can contact to solicit letters of recommendation.

The letter of recommendation from your Division Director must follow appendix 2 in the COM APT guidelines. Division Director letters should include the following paragraphs: introductory, education, research if applicable, scholarly publications, clinical practice if applicable, administration, and other activities and accomplishments.

If you have any questions, please contact Kristen Mulholland mulholllk@musc.edu.

---

**GRANT AWARD ACTIVITY**

**12.1.16-12.31.16**

<table>
<thead>
<tr>
<th>NAME</th>
<th>Type</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Cummings</td>
<td>Non-Competing Continuation</td>
<td>National Longitudinal Study of Tobacco Use (NLSTU) (Option Period 3)</td>
</tr>
<tr>
<td>Connie Guille</td>
<td>New</td>
<td>A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-547 Injection in the Treatment of Adult Female Subjects</td>
</tr>
<tr>
<td>Patrick O'Neil</td>
<td>New</td>
<td>Effect and Safety of Liraglutide 3.0 as an Anjunct to Intensive Behavior Therapy for Obesity in a Non-specialist Setting</td>
</tr>
</tbody>
</table>
KUDOS/WINS

- Dr. Leilani Lee received a research grant from the American Academy of Psychiatry and the Law Institute for Education and Research.

INCOMING CLASS FOR CHILD AND ADOLESCENT FELLOWSHIP

We are pleased to announce our incoming class for Child and Adolescent Fellowship for the 2017-2018 educational year!

Rachel Kennedy, MD – MUSC
Trey Bingham, MD – MUSC
Michael Sierra, MD – MUSC
Robert Ellis, MD – MUSC
Luke Miller, MD – Marshall University

A BIG thank you to Theresa Barnes, Ed Kantor, Kevin Gray, and Jeff Cluver. Thanks to everyone for their continued support in our educational and clinical efforts within the C&A Division! Looking forward to another great class!

SELECTED PUBLICATIONS


Addictive Behaviors is now accepting submissions for a special issue, *Ambulatory Assessment of Addictive Disorders*. Dr. Rachel Tomko (Tomko@musc.edu; Post-doctoral Scholar) and Dr. Erin McClure (McCluree@musc.edu; Assistant Professor) of the Addiction Sciences Division are Guest Editors for this issue and can be contacted directly with any questions or interest. Ambulatory assessment broadly refers to a number of remote monitoring techniques, including ecological momentary assessment (EMA), used to intensively study behavior in naturalistic settings. Submissions should utilize technology-based ambulatory assessment to enhance the study and treatment of addictive disorders. This may include substance use disorders and other addictive disorders (i.e., gambling disorder, internet addiction). Multimethod assessment approaches are particularly encouraged. Original research submissions, methodological papers, and review papers will be considered.

**The deadline for manuscript submission is July 1, 2017** for consideration for inclusion in this special issue. More information about this special issue can be found here: [https://www.journals.elsevier.com/addictive-behaviors/call-for-papers/special-issue-ambulatory-assessment-of-addictive-disorders](https://www.journals.elsevier.com/addictive-behaviors/call-for-papers/special-issue-ambulatory-assessment-of-addictive-disorders)
The McKnight Endowment Fund for Neuroscience supports innovative research designed to bring science closer to the day when diseases of the brain can be accurately diagnosed, prevented, and treated. To this end, the McKnight Memory and Cognitive Disorders Award assists scientists working to apply the knowledge achieved through basic research to human brain disorders that affect memory or cognition.

Use of Award Funds
We are interested in proposals that address memory or cognition under normal and pathological conditions. This includes proposals that address mechanisms of memory or cognition at the synaptic, cellular, molecular, genetic or behavioral level in animals, including humans. We are particularly interested in proposals that incorporate fundamentally new approaches, as well as those that involve human experimentation. Collaborative and cross-disciplinary applications are encouraged.

Projects restricted to the creation of conventional mouse knockouts in candidate disease genes identified by association studies, or to broadly overexpress those genes, are discouraged. In addition, projects to perform genetic interaction screens on disease genes in model organisms (yeast, worm, fly, fish) will not be considered, unless the project includes substantive specific aims that investigate the disease relevance of any new genes discovered in human or mammalian model systems.

Eligibility
Investigators who are conducting research at institutions within the United States are invited to apply. Applicants must be in tenured or tenure-track faculty positions; research faculty in annually renewable positions are ineligible. Applicants may not be employees of the Howard Hughes Medical Institute or scientists within the intramural program of the National Institutes of Health. Applicants may not hold another McKnight Award that would overlap with the Memory and Cognitive Disorders Award. We are interested in geographic, gender, and racial diversity and we encourage women and minorities, as well as scientists from all around the U.S., to apply. Funds may be used toward a variety of research activities, but not the recipient's salary. The candidate's other sources of funding will be considered when selecting awards.

Selection Process
For an application form, please visit our website at www.neuroscience.mcknight.org, or email or call the office of The McKnight Endowment Fund for Neuroscience (info@mcknight.org; 612-333-4220). The deadline for submission is March 27, 2017. In mid June, the selection committee will invite a small number of applicants to submit more detailed proposals, which will be due September 25, 2017. Funding begins February 1, 2018. Please email ONE PDF file that includes the application form (include one application form for each PI), a 2-page project description, and a 4-page NIH bio sketch to: neuro@mcknight.org (references may be outside the 2-page limit, but may be no more than two pages). Please do not include a budget. If you do not receive email confirmation of receipt of your LOI within 5 business days, please contact Eileen Maler at 612-333-4220 or emaler@mcknight.org.

The Endowment Fund will fund up to four awards, each providing $100,000 per year for three years.
UNMAKED
A Masquerade to Benefit Mental Health

THURSDAY, JANUARY 26, 2017 | 7 - 11 p.m.
REPUBLIC GARDEN + LOUNGE
462 King Street | Charleston, SC 29403

Whether it is anxiety, PTSD, depression or serious mental illnesses, 1 in 5 adults in America will experience mental health issues. Nearly 60% of adults with a mental illness did not receive mental health services in the previous year.

Join us for an evening of live music and dancing to raise awareness and funds for mental health in our community. Proceeds from the event will go directly to the Medical University of South Carolina’s Department of Psychiatry and Behavioral Sciences and the Institute of Psychiatry to support the important department wide initiatives in patient care, education and cutting edge research.

GENERAL ADMISSION TICKET: $15.00
VIP TICKET: $65.00

FOR MORE DETAILS AND TICKET PURCHASE VISIT:
http://bit.ly/2hAXYVh

SPECIAL SPONSORSHIP OPPORTUNITIES AVAILABLE | CONTACT (843) 792-1113 OR RICHET@musc.edu

Cocktail Casual and Masquerade Masks Optional.

---

Therapeutic Techniques & Special Populations in Psychiatry Series

AN OVERVIEW OF
DIALECTICAL BEHAVIOR THERAPY

Medical University of South Carolina | Strom Thurmond Building | Gane Auditorium | Charleston, SC

Friday, March 31, 2017 | 8:30 A.M. - 4:30 P.M.

Earn up to 6.5 CEUs*

Featuring
Amanda M. Stanley, Psy.D.
Clinical Psychologist
General Behavioral Health

Join us!

Dialectical Behavior Therapy (DBT) is a broad-based, integrative, behavioral treatment approach for the full spectrum of mood and personality disorders. Ineffective, ineffective, and even used in a path of irrational, self-destructive behavior, DBT has been found to reduce the symptoms of depression, anxiety, and other psychological disorders. This year, the conference will focus on the integration of DBT principles and techniques into various healthcare settings, including but not limited to, addiction treatment, pain management, and mental health care. Attendees will learn how to assess and manage patients with complex comorbid conditions and develop effective strategies for treatment.

Early Registration: $125.00
General Registration: $150.00
On-Site Registration: $175.00

Reduced Registration Rates:

Providers: $115.00
MUSC Providers: $115.00
Students and Trainees: $40.00

Register online at www.musc.edu/psychoevents

Questions? Contact us at psych.events@musc.edu (843) 792-0776

Get social with us!
Therapeutic Techniques & Special Populations in Psychiatry Series

INTRODUCTION TO PROLONGED EXPOSURE FOR THE TREATMENT OF PTSD

Medical University of South Carolina | Wellness Center | Room 204 | Charleston, SC
Friday, February 17, 2017 | 8:30 A.M. - 4:30 P.M.

Earn up to 6.5 CEU’s*

Join us

Trauma exposure is not rare. Roughly 60% of US people will experience at least one trauma in their lives. Unfortunately, many will develop trauma-related difficulties such as posttraumatic stress disorder. There have been a number of advances in the trauma field over the past two decades indicating several empirically supported treatment interventions for PTSD. Prolonged exposure is a gold standard trauma treatment approach guided by cognitive-behavioral principles. This workshop will provide clinicians with an introduction to the basic concepts of prolonged exposure including conducting in vivo and imaginal exposures as well as how to organize sessions. Participants will have an opportunity to observe role play examples as well as practice skills.

New this year! Reduced registration rates.

<table>
<thead>
<tr>
<th>Registration Rate</th>
<th>Early Registration</th>
<th>General Registration</th>
<th>On-Site Registration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Providers</td>
<td>$125.00</td>
<td>$150.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>MUSC Providers</td>
<td>$115.00</td>
<td>$140.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Students and Trainees</td>
<td>$40.00</td>
<td>$65.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>

REGISTER ONLINE AT WWW.MUSC.EDU/PSYCHEVENTS

Visit our website for further details & online registration for all of our events:
www.musc.edu/psychevents

Questions? Contact us at psych-events@musc.edu or (843) 792-0175

Get social with us!
SAVE THE DATE

June 1 - 2, 2017 • Charleston, SC

30th Annual Update in Psychiatry
Technology and Mental Health

Over the past three decades, important innovative technologies have transformed mental health care. To recognize our achievements and advancements in science and clinical practice, our 2017 conference will focus on technology and mental health.

Held in beautiful downtown Charleston at MUSC’s new Bioengineering Auditorium during Charleston’s premier cultural event, Spoleto Festival USA, this conference brings together psychiatrists, psychologists, counselors and social workers, as well as researchers, other physicians and healthcare professionals, for two days of networking and education. Be sure to join us this year for a networking reception with colleagues and community partners.

Charleston International Airport flies nonstop to 21 airports and 16 cities in the US. Come visit one of the most beloved cities in the world and see what everyone is talking about.

MARK YOUR CALENDAR!
Registration will open in February 2017

For conference details, visit us at www.musc.edu/psychevents, call (843) 792-0175 or get social with us and keep up-to-date on our year-round continuing education opportunities.
ONGOING STUDIES

Title: rTMS for Adolescent Depression -- upcoming in the next couple weeks
Contact: 843-792-5702
Description: We are investigating the safety and efficacy of repetitive TMS as a treatment for adolescent depression for those aged 12-21 years old. We are seeking adolescents of this age range who have not received sufficient benefit from at least one antidepressant medication trial. TMS is currently FDA approved for treating adult depression.

Title: rTMS for Bipolar Depression - current
Contact: 843-792-5702
Description: We are investigating repetitive TMS as a treatment for bipolar depression in conjunction with mood stabilizers in adults aged 22-68 years old. We are seeking treatment refractory patients with bipolar disorder. TMS is currently FDA approved for treating adult depression.

Title: Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving, Reactivity & Use
Contact: Amanda Smith, smitham@musc.edu, 792-6984
Description: The purpose of this double-blind, placebo-controlled study is to examine whether beta-adrenergic antagonist propranolol can attenuate cocaine-associated memories and thereby reduce cocaine craving, cue reactivity, and use in cocaine dependent participants. Participants will receive either placebo, 40mg, or 80mg of propranolol after each of two laboratory sessions of cocaine cue exposure. Participants will be evaluated on cocaine craving, physiological reactivity to cocaine cues, and cocaine use in follow-up sessions for 6 weeks.

Title: Assessing the Bite Counter as a Tool for Food Intake Monitoring: Phase II
Contact: Mary Harley harleyma@musc.edu 843-792-5428
Description: This study is a 15-week assessment of the possible utility of a wrist-worn device, the Bite Counter, in assisting the weight loss behavior change efforts of overweight and obese individuals. The Bite Counter tracks and analyzes wrist motions to identify those associated with taking bites of food and drinking beverages. It also has a step-counter feature. This study is designed to determine if using the Bite Counter with specific goals to reduce the numbers of bites and increase the numbers of steps will result in those changes.

Title: Girls Experiences in Middle School (GEMS)
Contact: Jennifer Powell, gems-study@musc.edu, 843-876-0567
Description: Participants are needed for the Girls’ Experiences in Middle School (GEMS) Study, a research study to understand girls’ thoughts, emotions, and experiences. Girls attending any middle school in the Charleston, SC area are eligible. If interested call, email, or visit www.musc.edu/gems and fill out a Parent Contact Form.

Title: Reward functioning, traumatic stress, and mental health in teen girls
Contact: Jesse Walker, walkerj@musc.edu, 843-792-7067
Description: Researchers at MUSC are recruiting teen girls aged 13-17 to participate in a research study using brain imaging (MRI, EEG) to understand connections between childhood experiences and mental health. Dates and times for participation are flexible. The study will involve 1 visit to the MUSC campus (2.5-3 hours). Compensation is provided.
Title: Psychological First Aid for Victims of Crime  
Contact: Dr. Michael McCart, mccartm@musc.edu, (843) 876-1800  
Description: This study aims to implement and refine research protocols required for a full-scale randomized clinical trial of Psychological First Aid (PFA) for adult victims of crime. PFA is a promising acute intervention designed to reduce the severity and duration of trauma-related distress. Law Enforcement Victim Advocates are being trained to implement PFA with adult crime victims. A pilot trial is comparing PFA to usual services on key mental health outcomes from baseline through 4 months post-baseline.

Title: Synthesizing HIV Behavioral Intervention Effectiveness in Developing Countries  
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800  
Description: This is a project in which we are conducting systematic reviews and meta-analysis on evidence of effectiveness of a variety of HIV behavioral interventions in developing countries.

Title: Phase II RCT of Comprehensive Triage HIV Prevention: Tanzania  
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800  
Description: The purpose of this study is to conduct a rigorous 3-year Phase II trial of a promising HIV prevention strategy designed to significantly reduce population-level HIV incidence in rural developing country settings with severe generalized HIV epidemics.

Title: Community-Based Combination HIV Prevention in Tanzania Women at Heightened Risk  
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800  
Description: This is a two-arm Phase II community randomized controlled trial of a community-based combination HIV prevention intervention among FSWs in Iringa, Tanzania. The combination package examined includes integrated biomedical, behavioral and structural components: The study will establish base rates of key outcomes including HIV incidence and viral load suppression, examine the socio-structural and behavioral pathways of the intervention, assess feasibility, acceptability and safety, and document preliminary effectiveness. (1) mobile HIV testing and risk reduction counseling; (2) service navigation to facilitate access to treatment and retention in care; (3) sensitivity training for HIV clinical care providers; (4) SMS text messages to promote adherence to care and ART; (5) venue-based peer education and condom distribution; and (6) a community drop-in center to promote cohesion and collective action to reduce stigma and discrimination.

Title: Dyadic-Based Diagnosis, Care & Prevention for Discordant Couples in Tanzania  
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800  
Description: The primary goal for the proposed study is to examine the feasibility, safety, and impact on improved care and prevention of novel strategies to identify and engage HIV sero-discordant couples in an integrated prevention and treatment intervention.
Title: A Phase 2, Efficacy, Safety, and Tolerability Study of ALKS 3831 in Schizophrenia with Alcohol Use Disorder.
Contact: Melissa Michel, michelm@musc.edu, 843-792-1901
Description: This study is designed to evaluate the efficacy, safety, and tolerability of ALKS 3831 in schizophrenia with AUD. ALKS 3831 is a combination of olanzapine, an approved antipsychotic treatment for schizophrenia, and samidorphan, a new medication. Potential subjects for this trial are adults with a diagnosis of schizophrenia and alcohol use disorder (AUD) with a recent change in symptoms. The study will test whether olanzapine with samidorphan will aide in lowering alcohol use for subjects at the same time that the combination of the two drugs lessens side effects of olanzapine such as weight gain.

Title: An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
Contact: Melissa Michel, michelm@musc.edu, 843-792-1901
Description: The main purpose of this study is to assess the long-term safety, tolerability, and effectiveness of esketamine nasal spray plus a newly initiated oral (taken by mouth) antidepressant in patients with treatment-resistant depression. All patients in this study will be treated with esketamine nasal spray plus a new oral anti-depressant. The new oral anti-depressant will be one of the following approved and marketed oral antidepressants: duloxetine (Cymbalta), escitalopram (Lexapro), sertraline (Zoloft), or venlafaxine extended release (Effexor XR). Recruitment ongoing.

Title: Internet Crimes Against Children: Development of a Typology of Offenders for Use in Prevention, Investigations and Treatment
Contact: Dr. Gregg Dwyer, 843-792-1461
Description: This study is based on the collection and analysis of data from Internet Crimes against Children (ICAC) investigated by ICAC Task Forces in 20+ states. The inferential analysis of perpetrator, victim and offense data and content analysis of Internet chats to solicit children serves to inform the mental health, social services, education and legal fields for use in forensic evaluations, treatment planning, criminal investigations, court proceedings and developing public safety strategies for protecting our communities’ youth. Funded by Office of Juvenile Justice and Delinquency Prevention grant # 2010-MC-CX-4003; joint with the University of So. Carolina.

Title: Protecting Children Online: Using Research-Based Algorithms to Prioritize Law Enforcement Internet Investigations
Contact: Dr. Dwyer. 843-792-1461
Description: Using data from ICAC Task Forces across the U.S. to develop empirically-based algorithms to assist law enforcement in prioritizing cases of: child pornography production over possession/distribution; online luring to meet a minor to commit sexual offenses, over luring restricted to online behavior such as sexual chat or exchanging pornographic images; hands-on sexual offense offenders against children over cases of offenders with no known history. Funded by Office of Juvenile Justice and Delinquency Prevention grant # 2011-MC-CX-0002; joint with University of South Carolina, Johns Hopkins University & University of Ottawa.
ONGOING STUDIES

Title: Rivastigmine Patch in Veterans with Cognitive Impairment Following Traumatic Brain Injury  
Contact: Katy Donovan donova@musc.edu (843) 724-2945  
Description: In light of the significance of memory deficits in persons with Traumatic Brain Injury (TBI), and the strong relationship between posttraumatic memory impairments and posttraumatic cholinergic dysfunction, this study examines the efficacy and safety of cholinesterase inhibitor rivastigmine (transdermal patch), an intermediate-acting cholinesterase inhibitor, in Veterans (ages 19 – 65 years old) suffering from posttraumatic memory impairment following TBI in a multicenter, randomized placebo controlled 26-week trial.

Title: Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)  
Contact: Olga Brawman-Mintzer, MD mintzero@musc.edu; (843) 724-2945  
Description: Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) is a Phase III, placebo-controlled, masked, 6 month, 10-center randomized clinical trial sponsored by National Institute of Aging involving 200 participants with Alzheimer's disease (AD). ADMET 2 is designed to examine the efficacy and safety of methylphenidate as treatment for clinically significant apathy in AD participants. ADMET 2 will enroll participants from real world settings such as outpatient, nursing home, and assisted living facilities and will examine the effects of methylphenidate on apathy and cognition. ADMET 2 will also conduct careful safety monitoring.

Title: Vitamin D and Type 2 Diabetes Study  
Contact: Mary Harley harleyma@musc.edu 843-792-5428  
Description: The goal of the Vitamin D and type 2 diabetes (D2d) study is to determine if vitamin D supplementation works to delay the onset of type 2 diabetes in people at risk for the disease and to gain a better understand how vitamin D affects glucose (sugar) metabolism. Researchers at twenty US sites will enroll people with pre-diabetes (people who have higher than normal blood glucose level but not high enough to meet the diagnosis of diabetes). The study will enroll participants over approximately 2 years and participants will be followed for approximately 3 years. Participants will receive either Vitamin D or a placebo by chance. Participants will take 1 pill a day for the duration of the study. Participants will visit the study site for up to 13 scheduled visits during their participation.

Title: Low Field Magnetic Stimulation (LFMS) and Subjective/Objective Measures of Sleep  
Contact: Allison Wilkerson, wilkersa@musc.edu, 843.792.4636  
Description: This study is a double-blind, sham-controlled crossover pilot study of low field magnetic stimulation (LFMS) in people with insomnia. Participants will receive 4 LFMS treatments total (2 active, 2 sham) and complete 5 overnight sleep studies to explore the relationship between low field magnetic stimulation and improvement of insomnia.
SUPPORTERS

Dr. Anthony C. Ross
ISLAND CHIROPRACTIC CENTRE

Mechanical treatment is complementary to medical care not an alternative

"Mechanical drivers for symptoms respond to mechanical corrections. Compensatory treatment reduces the symptoms not the mechanical cause’’

In network provider for State BCBS

- Class IV Laser
- Adjunctive Therapies
- Rehabilitation
- FDA Protocol Spinal Decompression

Anthony C. Ross DC, DAAPM, CCSP
3546 Maybank Highway
John’s Island, SC 29455
iccji@bellsouth.net
charlestonchiropractic.com

Call 843-559-9111

ZERO

Restaurant + Bar

Pre-Theater Dining ~ Cooking Classes
Chef’s Tasting Menus ~ Happy Hour

EASTON PORTER GROUP

DINNER TUESDAY–SUNDAY
Executive Chef Vinson Petrillo
Across from Gaillard Center at 6 George Street
ZeroRestaurantCharleston.com

CANNON GREEN
A GATHERING COMMON

Sunday Beats & Brunch ~ Chef’s Table
Private Events ~ Happy Hour

DINNER TUESDAY–SATURDAY
Executive Chef Amalia Scatena
103 Spring Street
CannonGreenCharleston.com